Chemomab Therapeutics Ltd. (CMMB) is a clinical-stage biotechnology company focused on developing therapeutics for inflammation and fibrosis, operating in the Healthcare sector. This analysis evaluates its Shariah compliance through financial screening, business activities, ESG factors, and index inclusions as of 2026-02-28. Financial ratios show strong compliance with low debt (0.68%) and liquidity (24.52%), and no non-permissible income identified. However, the company is not included in any major Shariah indices due to its small market capitalization, leading to an overall non-compliant status. ESG risks are low, with ethical medical research aligning with Islamic principles, though geopolitical location in Israel warrants monitoring.